Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.54 |
| ▸ | CNR2 | P34972 | 13/20 | 0.54 |
| ▸ | MARS1 | P56192 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522045 | 0.90 | CNR1 (0.55) | CNR1CNR2MARS1NTRK1SLC16A3 | |
| SCHEMBL5529097 | 0.90 | CNR1 (0.51) | CNR1CNR2MARS1SLC16A3SLC16A1 | |
| SCHEMBL5520051 | 0.89 | CNR1 (0.52) | CNR1CNR2MARS1NTRK1SLC16A3 | |
| SCHEMBL5524832 | 0.89 | CNR1 (0.54) | CNR1CNR2MARS1NTRK1 | |
| SCHEMBL5516429 | 0.89 | CNR1 (0.54) | CNR1CNR2MARS1NTRK1 | |
| SCHEMBL5525605 | 0.88 | CNR1 (0.53) | CNR1CNR2MARS1NTRK1SLC16A3 | |
| SCHEMBL5526957 | 0.88 | CNR1 (0.52) | CNR1CNR2MARS1NTRK1SLC16A3 | |
| SCHEMBL5520963 | 0.87 | CNR1 (0.52) | CNR1CNR2MARS1NTRK1SLC16A3 | |
| SCHEMBL5526712 | 0.86 | CNR1 (0.55) | CNR1CNR2MARS1NTRK1 | |
| SCHEMBL5529763 | 0.86 | CNR1 (0.40) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CNR1 76/4885CNR2 43/4885MARS1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.